Abstracts Archive - Page 128 of 2425 - ACR Meeting Abstracts

Abstract Number: 1800 • ACR Convergence 2024
WWC1 Regulates Type I Interferon Production Through Modulation of cGAS-STING Signaling in Keratinocytes
Bin Xu, Laura Cencer, Benjamin Klein, Shannon Loftus, Lam Tsoi, Johann Gudjonsson and J. Michelle Kahlenberg, University of Michigan, Ann Arbor, MI
Background/Purpose: Our recent study uncovered a role for dysregulation of the Hippo signaling pathway in systemic lupus erythematosus (SLE) keratinocytes (KCs) driven by overexpression of…
Abstract Number: 1748 • ACR Convergence 2024
Fracture Incidence Rates in Persons with Rheumatoid Arthritis by Disease Activity Level
Rachel Elam¹, Emma Kersey², Jing Li³, Gabriela Schmajuk⁴ and Laura Carbone⁵, ¹Augusta University, Evans, GA, ²University of California San Francisco, San Francisco, CA, ³University of California, San Francisco, San Francisco, CA, ⁴UCSF / SFVA, San Francisco, CA, ⁵Augusta University, Augusta, GA
Background/Purpose: Fracture incidence rates (IRs) are higher in men and women with rheumatoid arthritis (RA) than those without RA, especially for those with higher RA…
Abstract Number: 1760 • ACR Convergence 2024
A Phase 2 Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of a Mitogen-activated Protein Kinase-Activated Protein Kinase 2 (MK2) Inhibitor in Active Ankylosing Spondylitis
Walter Maksymowych¹, Robert Lambert¹, Paula Śliwinska-Stańczyk², Piotr Adrian Klimiuk³, Anusha Yeshokumar⁴, Elizabeth Cerullo⁴, Rebecca Kepich⁴, Chahin Pachai⁴ and Steven Greenberg⁴, ¹University of Alberta, Edmonton, AB, Canada, ²Centrum Medyczne ReumaPark, Warsaw, Poland, ³Medical University of Bialystok and Inter Clinic Piotr Adrian Klimiuk, Department of Rheumatology and Internal Diseases, Białystok, Poland, ⁴Bristol Myers Squibb, Princeton, NJ
Background/Purpose: CC-99677 (also known as BMS-986371) is a novel, orally bioavailable, small-molecule covalent inhibitor of mitogen-activated protein (MAP) kinase-activated protein kinase 2 (MK2). The MK2…
Abstract Number: 1765 • ACR Convergence 2024
CD8+ T Cells and Monocytes from Children with Macrophage Activation Syndrome Demonstrate Specific Transcriptional Changes Consistent with T Cell Activation and Expansion of Monocytes Shaped by Interferon and TLR Signaling
Susan Canny¹, Hannah DeBerg², Griffin Gessay², Ailing Lu³, Mary Eckert⁴, Andrea La Bella⁵, Hayley Waterman², Danish Nadeem², Susan Shenoi⁶, Joyce Hui-Yuen⁷, Daniel Campbell², Betsy Barnes⁸ and Jessica Hamerman², ¹University of Washington, Seattle, WA, ²Benaroya Research Institute, Seattle, WA, ³Northwell Health, Manhasset, NY, ⁴Seattle Children's Hospital, Seattle, WA, ⁵Cohen Children's Medical Center, Queens, NY, ⁶Seattle Children's Hospital and Research Center, Mercer Island, WA, WA, ⁷North Shore LIJ Health System, Great Neck, NY, ⁸Feinstein Institutes for Medical Science, Manhasset, NY
Background/Purpose: Macrophage activation syndrome (MAS), a form of secondary hemophagocytic lymphohistiocytosis (sHLH), is a potentially fatal complication of rheumatic diseases. MAS is characterized by a…
Abstract Number: 1825 • ACR Convergence 2024
Proteomic and Transcriptomic Analysis Reveal Elevated Senescent Signature in Systemic Sclerosis Fibrosis
Poulami Dey, Hiroshi Kato, Suiyuan Huang, Johann Gudjonsson, Dinesh Khanna, John Varga and Eliza Pei-Suen Tsou, University of Michigan, Ann Arbor, MI
Background/Purpose: Systemic sclerosis (SSc) is marked by persistent fibrosis affecting both the skin and internal organs. Some regard SSc as a manifestation of expedited aging,…
Abstract Number: 1571 • ACR Convergence 2024
Growth Differentiation Factor 15 Is a Serum Biomarker and Pathogenic Factor of Progressive Fibrosis in Systemic Sclerosis
Vishal Kakkar¹, Sunhwa Kim², Yingtao Bi³, Christopher Wasson¹, Stefano Di Donato⁴, Rebecca Ross⁵, Marco Di Battista⁶, Enrico De Lorenzis⁷, Thierry Sornasse² and Francesco Del Galdo¹, ¹University of Leeds, Leeds, United Kingdom, ²AbbVie, South San Francisco, CA, ³Abbvie, Worcester, MA, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, UK, Leeds, United Kingdom, ⁵Medicine and Health, University of Leeds, Leeds, United Kingdom, ⁶Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, UK, Pisa, United Kingdom, ⁷Catholic University of the Sacred Heart, Roma, Rome, Italy
Background/Purpose: In systemic sclerosis (SSc), interstitial lung disease (ILD) remains the leading cause of mortality. A decline in forced vital capacity (FVC) is considered a…
Abstract Number: 1812 • ACR Convergence 2024
Glycosylation Changes as Non-Invasive Biomarkers for Lupus Nephritis Detection and Prognosis
Aaron Angerstein¹, Richard Drake², Vishwajeeth Pasham², Bethany Wolf², Jim Oates² and Tammy Nowling², ¹Medical University of South Carolina, North Charleston, SC, ²Medical University of South Carolina, Charleston, SC
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease predominantly affecting women of childbearing age. Roughly 50% of SLE patients develop Lupus Nephritis (LN),…
Abstract Number: 1855 • ACR Convergence 2024
Identification of Autoreactive Cytotoxic T Cells in ANCA-Associated Vasculitis
Laura van Dam¹, Shady Younis², Jae-Seung Moon³, Mengrui Zhang⁴, Shima Parfasar⁴, Audra Horomanski³, orr Sharpe³, Jolijn van Leeuwen⁵, Tobias Lanz⁴, Cees van Kooten⁶, Onno Teng⁷ and William Robinson⁸, ¹Stanford, Palo Alto, CA, ²Stanford University, Stanford, CA, ³Department of Immunology and Rheumatology, Stanford University, Stanford, CA, ⁴Department of Immunology and Rheumatology, Stanford University, Stanford, ⁵Department of Nephrology, Leiden University Medical Center, Leiden, Netherlands, ⁶Department of Nephrology, Leiden University Medical Center, Leiden, ⁷Leiden University Medical Center, Leiderdorp, Netherlands, ⁸Division of Immunology and Rheumatology, Stanford University, and VA Palo Alto Health Care System, Stanford, CA
Background/Purpose: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a rare and severe autoimmune disease, characterized by a pauci-immune necrotizing vasculitis leading to inflammation and damage…
Abstract Number: 1767 • ACR Convergence 2024
Endothelial Cell-Driven JAG/NOTCH Signaling in Localized Scleroderma Patients
Theresa Hutchins¹, Anwesha Sanyal¹, Deren Esencan¹ and Kathryn Torok², ¹University of Pittsburgh, Pittsburgh, PA, ²Division of Rheumatology, Scleroderma Center, Department of Pediatrics, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA
Background/Purpose: Localized scleroderma is a rare autoimmune disease primarily affecting the skin and underlying tissue. While its exact pathogenesis remains unclear, studies suggest links to…
Abstract Number: 1701 • ACR Convergence 2024
STING Pathway Activity in SLE Patient Serum Correlates with NFkB Activation, Autoantibody Levels, and a Unique Cytokine Profile That Drives Disease Activity
Hyun Hee Kim¹, Haochen Jiang², Tatiana Ort³, Gary Sims³ and Richard Hanna⁴, ¹AstraZeneca, Gaithersburg, MD, ²University of Nebraska, Omaha, NE, ³Immunology Biosciences, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ⁴AstraZeneca, Dickerson, MD
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogenous systemic autoimmune disease which is associated with innate immune activation, type I IFN, inflammasome and NFkB-related cytokines.…
Abstract Number: 1715 • ACR Convergence 2024
Mortality Trends for Systemic Connective Tissue Diseases Across the United States from 1999 to 2020: A CDC-Wonder Database Analysis
Naima Khan¹, Yumna Furqan², Madiha Salman¹, Eman Ali¹, Wajeeh ur Rehman³, Ibtesam Allahi⁴, Farah Yasmin⁵ and Muhammad Sohaib Asghar⁶, ¹Dow University of Health Sciences, Karachi, Pakistan, ²Texas A&M School of Medicine, Dallas, TX, ³University Health Services Hospital, Johnson, NY, ⁴Allama Iqbal Medical College, Lahore, Pakistan, ⁵Yale University School of Medicine, New Haven, CT 06511, U.S.A., New Haven, CT, ⁶AdventHealth, Sebring, FL
Background/Purpose: The mortality burden of systemic connective tissue diseases (CTDs) is expected to rise in the U.S population because of multimorbidity and ageing. The primary…
Abstract Number: 1521 • ACR Convergence 2024
Contemporary Lupus Nephritis Treatment and Outcomes Among Patients with Systemic Lupus Erythematosus in the United States
Aakash Patel¹, Baijun Zhou², Hyon K. Choi³ and April Jorge¹, ¹Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital, Lexington, MA
Background/Purpose: Lupus nephritis (LN) is associated with excess morbidity and mortality, with prior studies finding a disproportionate impact on Black patients. We sought to determine…
Abstract Number: 1821 • ACR Convergence 2024
Single-Cell RNA SequencingBioinformatic Pipeline Optimized for Non-Coding GenesIdentified LINC01503 and MIR193-BHG as Potential Pathogenic Effectors in Systemic Sclerosis Fibroblasts
Sophie Wagner¹, Elena Pachera², Gino Andrea Bonazza³, Celina Geiss⁴, Astrid Hofman⁴, Laura Much⁴, Lumeng Li⁴, Pietro Bearzi³, Anna-Maria Hoffmann-Vold⁵ and Oliver Distler⁶, ¹University of Zurich, Schlieren, Switzerland, ²University Hospital Zurich, Zurich, Switzerland, ³Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Schlieren, Switzerland, ⁴Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁵Oslo University Hospital, Oslo, Norway, ⁶Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland
Background/Purpose: Long non-coding RNAs (lncRNA) are a class of transcripts that regulate gene expression. Currently, only few lncRNAs have been linked to SSc pathogenesis. As…
Abstract Number: 1864 • ACR Convergence 2024
S-4321, a Novel Dual-cell Bidirectional PD-1:FcγRIIb Selective Agonist Antibody for the Treatment of Autoimmune Disease
Julia Manasson¹, Marisella Panduro², Michael Cianci², Minasri Borah², Stephanie Grebinoski², Joshua Vitlip², Stephen Lutz², Ishan Sharma², Elliott Wittenberg², Allison Colthart², Samuel Perry², Maria Cecilia Ramello², Chelsea R. Parker Harp², Jyothsna Visweswaraiah², Ryan Peckner², Alex Pellerin², Heather Vital³, John Sundy⁴, Nathan Higginson-Scott², Kevin L. Otipoby² and Daniela Cipolletta², ¹Seismic Therapeutic, New York, NY, ²Seismic Therapeutic, Watertown, MA, ³Seismic Therapeutic, Lexington, MA, ⁴Seismic Therapeutic, Chapel Hill, NC
Background/Purpose: The dysregulation of immune checkpoint receptors on T cells and antigen presenting cells (APCs) drives autoimmunity while receptor agonism is expected to restore immune…
Abstract Number: 1775 • ACR Convergence 2024
Childhood-onset Sjögren Disease Has an Altered Peripheral Blood Immune Landscape Compared to Adult-onset Disease Characterized by Activated CD4+ T-cells Which Could Drive B-cell Dysregulation
Junjie Peng, Lucia Martin-Gutierrez, George Robinson, Elizabeth Jury and Coziana Ciurtin, University College London, London, United Kingdom
Background/Purpose: Childhood-onset Sjögren Disease (cSjD) is a rare, poorly understood autoimmune rheumatic disease with onset before 18 years. Differences in clinical presentation compared to adults/lack…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].